BioInformant

Your Global Leader in Stem Cell Market Research

Home » Stem Cell News » Press Releases » Page 12

Vita Therapeutics and I Peace announced a development program to generate iPS- derived differentiated cells for transplant therapy with an initial focus on FSHD (Facioscapulohumeral Muscular Dystrophy) using universal iPS cells

By Leave a Comment

Palo Alto, CA, July 10, 2025 –  Leading GMP cell CDMO I Peace, Inc., specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that the company has agreed with Vita Therapeutics (Vita) to jointly develop universal iPS cells that will be used for cell transplantation therapy.

GMP-grade iPS cells will be modified with proprietary, licensed gene editing technology to make a base platform hypoimmune line where Class I and II HLA genes that determine rejection have been depleted. These hypoimmune lines can be further customized in I Peace cGMP facilities. [Read more…]

Ciloa secures €6.5 million government funding from France 2030 ‘Innovation in biotherapies and biomanufacturing’ to develop drug candidate for treatment of obesity and type 2 diabetes

By Leave a Comment

  • ‘DIADEME’ project awarded €6.5 million in government funding via France 2030, enabling Ciloa to advance the development of its bio-drug APN-sEV (Adiponectin associated with exosomes), the world’s only recombinant, stable and functional form of Adiponectin
  • First preclinical results confirm remarkable therapeutic potential in treatment of several metabolic diseases, in particular type 2 diabetes and obesity, affecting around two billion patients worldwide
  • Ciloa plans to use funding to implement biomanufacturing of candidate APN-sEV and demonstrate that innovative biotherapy meets all safety criteria to enter clinical phases I and IIa in treatment of obesity and type 2 diabetes

[Read more…]

Cellino’s iPSC Manufacturing Technology Receives FDA Advanced Manufacturing Technology (AMT) Designation

By Leave a Comment

AMT Designation Positions Cellino to Accelerate the Development of Scalable, Personalized Regenerative Medicines

CAMBRIDGE, Mass. — Cellino, a leader in advanced biomanufacturing, today announced that its optical biomanufacturing technology for generating induced pluripotent stem cells (iPSCs) has received the FDA’s Advanced Manufacturing Technology (AMT) designation from the Center for Biologics Evaluation and Research (CBER). This prestigious designation highlights the transformative potential of Cellino’s automated technology for scaling up high-quality iPSCs to industrialize next-generation regenerative therapies. [Read more…]

STEMCELL Technologies Launches STEMprep™ System to Streamline Tissue Dissociation in Research

By Leave a Comment

New instrument automates tissue processing for researchers in cancer, immunology and other science fields

VANCOUVER, British Columbia, June 27, 2025 –– To help scientists accelerate their workflows, STEMCELL Technologies has commercially launched the STEMprep™ Tissue Dissociator System—a new benchtop instrument that automates, standardizes, and streamlines tissue dissociation, the process of breaking down tissue samples into single-cell suspensions for research purposes. [Read more…]

Applied StemCell Launches hiEX™ Research iPSC Exosomes to Power Next-Generation Regenerative Medicine Research

By Leave a Comment

MILPITAS, Calif., June 24, 2025 — Applied StemCell, a leading provider of advanced stem cell and gene editing technologies since 2008, today announced the release of hiEX™ Research iPSC Exosomes, a new research-use-only product designed to enable scientists to explore the therapeutic potential of iPSC-derived exosomes in areas such as wound healing, aging, and nerve regeneration. [Read more…]

Shopping cart0
There are no products in the cart!
Continue shopping
0